Biowebtronics Biotech, startups, web development and internet of things.

In silico drug discovery Co.s

This is a post of some notes I made in an attempt to aggregate companies where in silico drug discovery is a main part of their business. Most of the text about the companies is straight from the company website.

Many thanks to @simonbayley, @rowan_UK and @rscoffin for the suggestions.

If you have anymore let me know on twitter @bennmiles

Cheers,

-B

Nimbus US

Nimbus Discovery harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. Nimbus focuses on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Nimbus’ robust pre-clinical pipeline includes novel agents for the treatment of cancer, metabolic disease and inflammation. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design.

http://www.nimbusdiscovery.com/

Molplex UK

Molplex is a new class of pharmaceutical company, using its innovative technology to identify and optimise novel treatments for infection, cancer and other serious diseases.

Its pipeline of small-molecule therapeutics is driven by our proprietary platform for drug optimisation, Optiplex - a highly scalable system combining automated decision-making with laboratory automation. Optiplex delivers safer and more effective drugs at radically lower cost.

Molplex aims to discover novel treatments quicker and more effectively, improving the health of patients around the globe.

http://www.molplex.com/

Domainex UK

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record of 5 Candidate Drugs delivered in 5 years.

Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry andcomputational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.

Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 and a number of epigenetics related lysine methyltransferases.

http://www.domainex.co.uk/

Biofocus UK

Collaborating with BioFocus' computational team puts leading informatics, molecular modeling and QSAR expertise at your fingertips. Working closely with our colleagues in screening, structural biology, FBDD, medicinal chemistry and with a leading position in the design of our fragment and SoftFocus libraries, our capabilities are available as part of hit identification, hit expansion, hit-to-lead and lead optimization programs.

In addition to contributing to client programs carried out at BioFocus we are able to provide computational chemistry consultancy to troubleshoot and contribute fresh ideas to your projects.

http://www.biofocus.com/

Evotec Switzerland / 600 employees…

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation.

http://www.evotec.com/

Cresset Group UK

Cresset’s consultants work with a wide range of therapeutically relevant targets and also in many disease areas in which the biological target is unknown. The majority of these projects involve ligand focused virtual screening.

Virtual screening is an effective means of switching chemical series to identify new intellectual property. It is also a fast and cost effective way of testing several different hypotheses.

http://www.cresset-group.com/

comments powered by Disqus